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Summary 
Accumulating evidence has implicated the proteasome in the processing of proteins along the 
major histocompatibility complex (MHC) class I presentation pathway. The availability of po- 
tent proteasome inhibitors provides an opportunity to examine the role ofproteasome function 
in antigen presentation by MHC class I molecules to CD8 + cytotoxic T lymphocytes (CTLs). 
We  have investigated the processing and presentation  of antigenic  epitopes  from influenza 
hemagglutinin in target cells treated with the inhibitor of proteasome activity MG132. In the 
absence of proteasome activity, the processing and presentation of the full-length hemaggluti- 
nin was abolished, suggesting the requirement for proteasome function in the processing and 
presentation  of the  hemagglutinin glycoprotein.  Epitope-containing translation products  as 
short as 21 amino acids when expressed in target cells required proteasome activity for process- 
ing and presentation of the hemagglutinin epitope to CTLs. However, when endogenous pep- 
tides of 17 amino acids or shorter were expressed in target cells, the processing and presentation 
of epitopes contained in these peptides were insensitive to the proteasome inhibitor. Our re- 
sults support the hypothesis that proteasome activity is required for the generation of peptides 
presented by MHC class I molecules and that the requirement for proteasome activity is depen- 
dent on the size of the translation product expressed in the target cell. The implications of these 
findings are discussed. 
T 
he antigen receptor on CD8 + T  lymphocytes recog- 
nizes short peptide fragments ofpolypeptides bound to 
MHC class I molecules (1, and for review see 2). These pep- 
tide fragments are derived from polypeptide precursors of 
self and foreign proteins found primarily in the cell cyto- 
plasm  (3). The  peptide  fragments generated in  the  cyto- 
plasm are transported from the cytosol to the endoplasmic 
reticulum (ER) 1 through the action of the ATP-dependent 
transporter for antigen presentation (TAP) complex, which 
is encoded by two genes, TAP- 1 and TAP-2, located in the 
MHC locus (4-7). 
The characteristics  of peptide transport mediated by the 
TAP complex for presentation to MHC class I molecules 
have been investigated by a number of groups using iso- 
lated  microsomes  or  permeabilized  cell  systems  (8-11). 
These analyses have provided information on the size and 
1Abbreviations used in this paper: aa, amino acid; ER, endoplasmic  reticu- 
lure; HA, hemagglutinin;  LMP, latent  infection  membrane protein; TAP, 
transporter for antigen  presentation;  VV, vaccinia  virus. 
sequence  of peptides  optimally transported  by  the  TAP 
transporter.  In contrast, the process of peptide fragmenta- 
tion in the cytosol and the type and properties of the pro- 
tease(s)  involved in peptide generation in the cytosol are 
less well understood. Several lines of evidence have impli- 
cated  the  high  molecular weight  multicatalytic cytosolic 
protease complex, the proteasome, as a critical enzyme for 
the processing of  protein antigens in the cytosol for presen- 
tation along the MHC class I processing pathway (12-14). 
Indeed, two subunits of the proteasome (LMP-2 and LMP-7 
[for latent infection membrane proteins  1 and 2])  are  en- 
coded by genes within the MHC locus (15-16). 
Because proteasome activity is required for normal cell 
function and viability, it has not been possible  to eliminate 
permanently proteasome activity in living cells and assess 
the impact of the proteasome deficiency on antigen pro- 
cessing  and CD8 §  T  cell recognition. Recently, Rock et 
al.  (17) described a class of agents that inhibit the protea- 
some proteolytic pathway in cells. These agents are peptide 
aldehydes that act selectively to inhibit the major peptidase 
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hibit the degradation of ubiquitinated protein substrates by 
the  26S  particles. With  the  development  of such  highly 
specific proteasome inhibitors (17,  18), the effect of inhibi- 
tion  of proteasome  function  on  antigen  processing  and 
CD8 + T  cell recognition can now be assessed. 
In this report, we examined the effect of the proteasome 
inhibitor  MG132  on  the  processing  and  presentation  to 
CTLs  of endogenously  expressed intact influenza hemag- 
glutinin (HA) protein, truncated forms of the HA protein, 
and  minigene  products  encoding  various  lengths  of HA 
protein containing CD8 §  T  cell epitopes. We  found that 
the  presentation of the  full-length HA  protein,  truncated 
HA proteins, and minigene products of 21  amino acids (aa) 
or longer to CTLs were sensitive to the proteasome inhibi- 
tor MG132 but that the presentation to CTLs  of epitopes 
in translation products up to 17 aa in length was insensitive 
to the MG132.  These results suggest that proteasome activ- 
ity is required only for the processing and presentation of 
protein  products  longer  than  17  aa.  The  significance  of 
these results for proteasome function and antigen process- 
ing is discussed. 
Materials and Methods 
Viral Constructs.  The  minigene constructs were produced as 
described (19).  The sequence of translation products used in this 
study is shown in Table 2. The construction of the recombinant 
vaccinia virus (VV) HAAR1 has been described previously (20). 
The HA gene product expressed by this VV has a deletion of 166 
aa in  the  middle of HA,  i.e.,  HA residues 224-356  (20).  The 
Sindbis virus vector THA expresses a truncated A/JAP/57 HA 
product consisting of HA residues 1-266 (19).  All truncated HA 
products and minigene products were expressed in target ceils by 
use of recombinant Sindbis or Vaccinia vectors as noted in the text. 
CTL Clones.  The  generation,  characterization, and mainte- 
nance of CTL clones 14-1  and 40-2 are described in detail else- 
where (2). 
Virus Infection.  Log-phase P815  cells were infected with re- 
combinant VVs at a multiplicity of infection of 10 and with Sind- 
bis viruses at a multiplicity of infection of 20 in medium consist- 
ing of 1%  FCS in PBS.  Infection with influenza A/JAPAN/57 
was carried out essentially as described (20),  with the following 
modifications. After  20  rain  incubation  of cells with  virus  at 
37~  P815 cell samples were split, and the proteasome inhibitor 
MG132 (Myogenics, Inc., Cambridge, MA) was added to the test 
sample at a final concentration of 10-50 I-tM in MEM (GIBCO 
BR.L,  Gaithersburg, MD)  as noted in the text. The control cell 
sample received medium without MG132.  The cells were incu- 
bated at 37~  for 40 min. The two cell samples were then washed 
once to remove unbound virus, and MG132-containing medium 
was added to the test sample, followed by 25 btCi of Na[SlCr]204 
(DuPont/New  England Nuclear, Boston, MA). The target cells 
were incubated for 3 h at 37~  to allow viral gene expression and 
SICr uptake. Control P815 cells were infected and S*Cr labeled in 
parallel in medium without MG 132. 
CTLAssay.  The  in  vitro  cell-mediated cytotoxicity assays 
were carried out for 6 h as described (20).  Since cytoxicity assays 
were performed in medium without MG132, brefelden A  (21) at 
a final concentration of 5 b~g/ml was added to the assay medium 
to block export of nascent MHC class I molecules to the surface 
of target cells during the cytotoxicity assay. 
FACS~Analysis.  Log-phase P815  cells were infected at 4~ 
with A/JAPAN/57 virus as above and further incubated for 20 
man  at 37~  Cell samples were washed once and then divided 
into three groups. Cells were either incubated in medium supple- 
mented with MG132 to a final concentration of 10 or 50 ~M or 
in  medium  without  the  inhibitor.  After 4  h  of incubation  at 
37~  the  cells  were  washed  and  treated with  a  murine  mAb 
against the A/JAPAN/57 HA, followed by a fluorescein-conju- 
gated rabbit antibody to mouse Ig (Southern Biotechnology As- 
sociates, Inc., Birmingham, AL). Flow cytofluorometric analysis 
was carried out on a FACScan  |  flow cytometer (Becton Dickin- 
son & Co., Mountain View, CA). 
Results 
Inhibition of Proteasome Activity Blocks HA Presentation.  Re- 
cendy, a class of aldehyde inhibitors has been identified that 
can selectively inhibit the enzymatic activity of the protea- 
some complex (17). One of these inhibitors, MG132, is par- 
ticularly potent, with a/~  of 4  ~M  (22).  Since the protea- 
some has been implicated in the fragmentation of cytosolic 
proteins for presentation to MHC  class I-restricted CTLs, 
we wanted to examine the effect of proteasome inhibition 
by MG132 on the presentation of the A/JAPAN/57 HA to 
H-2Ka-restricted CTLs. Although the HA is a type I mem- 
brane glycoprotein with a signal sequence for ER  translo- 
cation, processed peptides for presentation to MHC  class I- 
restricted CTLs are normally generated by fragmentation of 
a cytosohc form of the HA translation product (23). 
To  examine  the effect of MG132  on  HA presentation, 
P815 target cells were infected with A/JAP/57 virus for 40 
min at 37~  in the presence of this inhibitor and further in- 
cubated with  Na[SlCr]204 for 3  h  more at 37~  to  allow 
viral gene expression during radiolabel uptake. After incu- 
bation at 37~  the infected target cells were suspended in 
medium  without  MG132  and  tested  for  recognition  by 
HA-specific CTLs in a standard chromium release cytotox- 
icity assay. MG132 was excluded from the cytotoxicity as- 
say to avoid potential nonspecific toxicity to the inhibitor 
on  CTL  function  or target cell viability during the  assay. 
Since MGI32  is a reversible inhibitor of proteasome activ- 
ity,  MHC  class  I  molecules  containing  newly  processed 
HA peptides could be generated in infected target cells by 
the  now  active  proteasome  during  the  cytotoxicity assay 
(17). To circumvent this problem, cytotoxicity assays were 
carried out in the presence ofbrefeldin A, which blocks the 
transport of nascent MHC  class I molecules from the ER to 
the cell surface (21). 
Fig.  1  shows  the  effects  of MG132  on  recognition  of 
processed HA by two Ka-restricted CD8 + CTL clones: 14-1, 
which  is directed to  the  HA 204-212  epitope,  and  40-2, 
which is directed to the HA 210-219  epitope (24).  Treat- 
ment of the target cells with MG132 during influenza viral 
gene  expression abolished target cell recognition by these 
HA-specific CTLs. Similar results were obtained when the 
infection  of target  cells was  carried out  with  either  a  re- 
combinant  W  expressing  the  full-length  A/JAP/57  HA 
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expressing a truncated HA gene encoding HA residues 1-266 
(Fig. 1 c) (19). Inhibition of CTL recognition by MG132 was 
dependent  on  the  dose  of inhibitor used to  block protea- 
some  activity; MG132  at  a  final concentration  of 50  p~M 
was found to produce maximum inhibition (Fig. 1 c). 
MG132  treatment  did not  have  a  nonspecific  effect  of 
the susceptibility of target cells to lysis by CD8 +  CTLs. As 
Fig. 1 d shows, MG132-treated target cells were as efliciendy 
lysed as untreated target cells after pulsing with a synthetic 
peptide corresponding to  the  HA 204-212  epitope. Also, 
to  examine the possibility that MG132  affects the  expres- 
sion of the HA gene in influenza-infected target cells, the 
level of HA protein expression on the surface of treated or 
untreated influenza-infected P815  cells was determined by 
flow cytofluorometric analysis. As Table  1 shows, cell sur- 
face HA  expression of A/JAP/57-infected P815  ceils was 
comparable both in control infected target cells and in cells 
infected and maintained in either 10 IzM or 50 p,M MG132. 
Endogenous Presentation of Minimal Epitopes Is Insensitive to 
MG132.  If MG132  inhibits  CTL  recognition  of target 
cells by blocking proteasome-dependent fragmentation of 
the  HA,  then  target  cells that  express  a  preprocessed HA 
epitope  should  not  be  sensitive to  inhibition by MG132. 
To examine this, we constructed recombinant Sindbis viruses 
(Table 2, SIN204(10) and SIN210(10)  expressing minigenes 
encoding 10 aa peptides corresponding to the minimal HA 
epitopes recognized by clone 14-1, i.e., HA 204-212,  and 
by clone 40-2,  i.e., HA 210-219.  As Fig. 2  demonstrates, 
MG132  did not inhibit the presentation of these minimal 
minigene products when  expressed in the cytoplasm of in- 
fected cells. 
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Figure 1.  The processing and presentation of 
influenza HA expressed during viral infection is 
blocked by the proteasome inhibitor MG132. 
Log-phase P815 cells were infected, with either 
influenza virus (A), a recombinant W  express- 
ing full-length HA (B), or a Sindbis virus vector 
expressing the NH2-terminal 266 aa of the A/ 
JAPAN/57 HA (C), and incubated in medium 
supplemented with MG132 to a final concen- 
tration  of 50  IzM  (and 10  p~M in C)  as de- 
scribed (see Materials and Methods). In D, un- 
infected cells were incubated in medium with 
or without  MG132 as described above for in- 
fected cells, and the uninfected target cells were 
then  loaded with  the  HA 204-212  peptide at 
the peptide concentrations indicated in D. Cy- 
totoxicity assays were carried out for 4-6 h in 
the  presence of 5  p~g/ml brefeldin  A.  CTL 
clones 40-2 and 14-1 were used at an E/T ratio 
of 5:1. Values are the mean 51Cr release of qua- 
druplicate wells with SEs (<5% of mean values) 
not displayed on the histograms or fines. 
MG132 Inhibition Is Dependent on the Length of the Endog- 
enous Peptide Product.  Since MG132  inhibited the endog- 
enous presentation of the full-length HA translation prod- 
uct but not the minimal CTL epitope, it was of interest to 
determine whether MG132 sensitivity was dependent on the 
size of the translation product containing the HA epitope. 
Since  the  SIN  THA  virus tested  above  (see  Fig.  1  c)  ex- 
pressed a truncated form of the A/JAP/57 HA and MG132 
inhibited the  recognition of target  cells infected with  the 
SIN  THA  virus by CTLs,  expression of a  nonnative  HA 
translation product per se was  not  suflficient to  overcome 
the  inhibitory effect  of MG132.  A  similar result was  ob- 
tained when we examined the effect of MG132 on presen- 
tation  of another  truncated  HA  gene  product,  HA~IL1 
when  it was  expressed by  a  recombinant  vaccinia vector 
(Fig. 3  a). The HAAR1 gene construct has an in-frame de- 
Table 1.  Influenza  HA Expression in MG132-treated Cells 
Treatment*  Mean Fluorescencer 
Uninfected  2 
Influenza infected  44.7 
Influenza +  10 tzM MG132  60.2 
Influenza +  50 p,M MG132  62.3 
*P815 cells were infected and treated with MG132  cells as described 
(Materials and Methods). After 4 h incubation at 37~  in medium with 
or without MG132,  cell surface HA expression was  determined  by 
flow cytometry. 
*Values are mean of 5 ￿  104 cells sampled in arbitrary units. Table 2.  Viral  Expression Vector 
Length 
Virus and vector*  HA sequence~  (aa) 
SIN 210(10) 
SIN 204(10) 
SIN 204(13) 
SIN 204(17) 
SIN 204(21) 
SIN 204(28) 
SIN 204/210(34) 
SIN 204/210(46) 
W  204/210(46) 
SIN THA 
VV HAARI 
Influenza 
VV HA 
MA YS VGTS TL  10 
MYQNVGTYVS  10 
MSTLQNVGTYVS  13 
ML YQNVGTYVSVGTS  TL  17 
METEQRT  L YQNVGTYVSVGTZ  21 
METEQRT  L YQNVGTYVSVGTHMEQNGAZ  28 
METEQRT  L YQNVGTYVSVGTS  TLNKR  I LDATPQZ  34 
METE QR T  L YQNVG TYVS VG TS TLNKRD PRRYA P MIRPAKLDVLPRNZ  46 
METE QR T  L YQNVG TYVS VG TS TLNKRD PRRYA P MIRPAKLDVLPRNZ  46 
NH2-terminal 266 aa  266 
Internal deletion of 165 aa  396 
Full-length HA  561 
Full-length HA  561 
*Vector designation indicates viral vector. SIN, Sindbis; VV, vaccinia. Number designations 204 and 210 indicate presence of coding sequence for 
204-212  or 210-219  epitopes. Values in parentheses correspond to length of translation product. 
*The sequences corresponding to HA 204-212  are underlined, and the sequences corresponding to HA 210-219  are italicized. 
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Figure 2.  MG132 does not inhibit the processing and presentation of 
minimal minigene products. Log-phase P815 cells were  infected with 
Sindbis virus vectors expressing 10-mer peptides corresponding to  the 
minimal HA 204-212  (A) or HA 210--219 (B) epitopes recognized by 
CTL clones 14-1 and 40-2, respectively. Infected cells were treated with 
50 I~M MG132 and assayed for lysis as described in Fig. 1. CTL clones 
were used at an E/T ratio of 5:1. The HA protein sequences encoded by 
the SIN 204(10) and the SIN 210(10) virus vectors are shown in Table 2. 
letion in the A/JAP/HA cDNA that eliminates the coding 
sequence for the middle third of the A/JAP/HA, i.e., HA 
224--356  (19),  but retains the HA 204-212  and HA 210- 
219 sites. As Fig.  3 a shows, MG132 inhibits presentation 
of the HA epitopes expressed from the VV HAIR1 vector. 
We  previously  reported  that  the  46-aa  product  of a 
minigene encoding the HA residues encompassing the HA 
204-212 and HA 210-219 sites can be precessed and pre- 
sented to CTLs (25). In view of our finding that target cells 
expressing the minimal epitopes were insensitive to inhibi- 
tion by MG132, it was of interest to determine whether an 
endogenous translation product of intermediate length, i.e., 
46  aa, would be insensitive to this inhibitor of proteasome 
activity. This was not the case (Fig. 3, b and c). The presen- 
tation  of the  46-aa  minigene  product  expressed in  target 
cells  by  either  a  Sindbis  or  vaccinia  expression  vector 
showed as sensitive an inhibition by MG132 as that in cells 
expressing the longer translation product. 
The  sensitivity of endogenous  46-aa peptide to  inhibi- 
tion by MG132 was striking in view of the insensitivity of 
endogenously expressed minimal peptide epitopes to inhi- 
bition  by MG132  (see  Fig.  2).  This  raised  the  possibility 
that in the  absence of proteasome activity, only a  peptide 
corresponding to the minimal CTL epitope could be pre- 
sented.  It was  therefore  of interest to  determine  whether 
endogenous  peptides  of lengths  longer  than  the  minimal 
epitope were  inhibited by MG132.  To  examine  this,  we 
constructed synthetic minigenes encoding the minimal HA 
204-212  epitope flanked by native A/JAP/57 HA residues 
with total product lengths of 13,  17, 21, 28, or 34 aa. Fig. 4 
shows  the  effect  of MG132  on  the  recognition  of target 
cells expressing these nfinigene products by use of recom- 
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Figure  3.  The presentation of truncated HA proteins and large mini- 
gene products is sensitive to proteasome inhibition. Log-phase P815 cells 
were infected with the recombinant W  HAAIL1 (A), or with a Sindbis 
virus (/3) or VV vector (C)  expressing a peptide of 46 aa containing the 
HA 204-212 and HA 210-219 epitopes. MG132 treatment (50 IxM final 
concentration) and CTL assays were carried out as in Fig. 1 with the HA 
210-219-specific clone 40-2 (A) or the HA 204-212--specific clone 14-1 
(A-C). E/T ratios were 5:1, except where noted in B. The sequence of 
the 46 aa HA peptide is listed in Table 2. 
binant  Sindbis  virus vectors.  Although  in  the  absence  of 
MG132 translation products of 13 and 17 aa were not rec- 
ognized as efficiently as the minimal HA 204-212 epitope, 
MG132  did not  inhibit  presentation  of these  poorly pre- 
sented minigene products.  In contrast, presentation of en- 
dogenous peptides of 21, 28, or 34 aa to clone 14-1 was in- 
hibited by MG132.  The 34-aa product also contained the 
intact  HA  210--219  epitope.  Presentation  of this  epitope 
when expressed as part of the 34-aa translation product was 
also  inhibited by MG132  (data not shown).  These results 
indicate that only endogenous peptide products of 21 aa or 
longer are sensitive to inhibition by MG132. 
The alternative interpretation for our observation might 
be  that  minigene  products  of any  length  with  three  or 
fewer NH2-terminal residues to a minimal epitope do not 
require  proteasome function, whereas translation products 
with seven or more NH2-terminal flanking residues require 
proteasome-dependent proteolysis for processing.  To  test 
this  possibility,  we  carried  out  the  experiment using  the 
minigene construct where the HA 204-212 epitope is con- 
tained  within  44-aa translation  product  and  is flanked by 
three NH2-terrninal residues (Met, Arg, Thr). MG132 in- 
hibited the processing and presentation of the HA 204-212 
epitope  to  CTLs  (data  not  shown).  This  suggests  that 
MG132  sensitivity is not related to the  number of NH  2- 
terminal residues. 
Discussion 
In this report we have examined the  effect of the pro- 
tease inhibitor MG132  on the processing and presentation 
of the  influenza HA to  CD8 +  CTLs.  We found that this 
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Figure  4.  The proteasome dependence of presenta- 
tion of short translation products. Sindbis virus vectors 
encoding translation products of 13 aa (A),  17 aa (B), 
21 aa (C), 28 aa (D), and 34 aa (E) were used to infect 
target cells in the presence (open squares) or absence 
(closed squares) of the MG132 (50 ~M final concentra- 
tion).  Incubation  of target  cells  and  assay conditions 
were as described (Fig.  1). Clone 14-1 was used at the 
indicated E/T ratios. The sequences of the HA transla- 
tion products are listed in Table 2. 
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HA translation product and T cell epitopes present in trans- 
lation products of 21 aa or longer, but that MG132 has no 
effect on the presentation of epitopes contained in transla- 
tion products of 17 aa or less. These findings suggest that 
for  these  viral  CTL  epitopes,  at  least,  peptide  products 
shorter than 21 aa can be processed and presented to CTLs 
by  a  proteasome-independent  mechanism.  These  results 
further raise  the possibility that most peptides longer than 
17-20 aa may require proteasome-dependent processing to 
be presented in association with MHC class I molecules. 
Enzyme inhibitors have been used  extensively to assess 
the role and function of proteases in biological processes. 
An important concern in the use of inhibitors is whether 
the inhibitor is selective in its action. For example, the pro- 
teasome inhibitor MG132 can affect the activity oflysoso- 
mal enzymes, e.g., cathepsin B (17), but lysosomal enzymes 
are unlikely to be important in the processing of the cyto- 
solic proteins examined in this report. Several other lines of 
evidence in this report suggest that MG132 inhibited anti- 
gen processing and presentation by a specific mechanism. 
First,  MG132-mediated inhibition was observed when the 
HA was expressed either during influenza virus infection or 
after expression of the HA by VV or Sindbis virus vectors. 
Since each of these viruses uses a different replication strat- 
egy, the  effect of MG132  on processing and presentation 
cannot be easily attributed to MG132-mediated inhibition 
of a cellular or viral function necessary for HA gene expres- 
sion in infected target cells.  Indeed, the synthesis and cell 
surface  expression of the  HA in  influenza-infected target 
cells were unaffected by MG132 treatment.  Second, since 
the inhibitor is not included in the cytolysis assay, suppres- 
sion of CTL function by MG132  cannot account for the 
lack  of CTL  recognition.  Also,  since  exposure  of target 
cells  to  MG132  did not  affect the  subsequent loading of 
synthetic peptides on target cells and the recognition of the 
target cells by CTL, nonspecific effects of the drug on the 
susceptibility of target cells to lysis appear unlikely. Finally, 
when  translation  products  of increasing length  were  ex- 
pressed in target cells, inhibition of antigen presentation by 
MG132  was  dependent  on  the  length  of the  translation 
product containing the CTL epitope. Taken together, these 
observations suggest that MG132  is highly selective in its 
action  and  that inhibition  of proteasome-dependent pro- 
teolytic activity likely accounts for the inhibitory effect of 
this compound on antigen presentation. 
Since the proteasome complex is essential  for cell viabil- 
ity and cell cycle progression (22),  mutant  cell  lines defi- 
cient in this activity are currently not available.  Therefore, 
the role of this cytosolic protease complex in antigen pro- 
cessing  and  presentation  has  been  difficult  to  evaluate. 
Since two proteasome subunits,  LMP-2  and  LMP-7,  are 
encoded by genes within the MHC locus (15,  16) in close 
proximity to  the  genes  encoding the  TAP  proteins,  the 
proteasome  and  particularly  proteasome  complexes  con- 
taining LMP-2 and LMP-7 have been suggested to play a 
role in  the processing of polypeptides for presentation to 
MHC class I molecules (12-14).  However, cell lines lack- 
ing the genes for LMP-2 and LMP-7 have been reported to 
have normal levels of MHC  class I molecules at their cell 
surfaces  and  to  function normally in  antigen presentation 
by class I molecules (26,  27). Although such results  argue 
against  the  importance  of the  proteasome in  general  and 
the  LMP-2  and  LMP-7  proteins  in  particular in  antigen 
processing, mice that have been made genetically deficient 
in LMP-2 and LMP-7 function by targeted gene disruption 
do show abnormalities in the processing of certain antigens 
(28,  29).  To test directly the  contribution of the protea- 
some in antigen presentation, it is necessary to specifically 
inhibit  this  protease  activity  in  antigen-presenting  cells. 
The development of inhibitors of proteasome activity now 
provides  investigators  with  the  opportunity to  assess the 
role of the proteasome complex in antigen processing for 
MHC  class 1 presentation. The results  reported here from 
studies  using  endogenously  expressed  antigens  and  from 
earher proteasome inhibition studies by l<ock et al. (17) us- 
ing microinjection of exogenous proteins into target cells 
directly implicate the proteasome in the processing of pro- 
teins for presentation by MHC class I molecules. 
The antigenic peptides  bound  to mature  MHC  class I 
molecules are predominately 8-11  aa  in  length  (30).  On 
the basis of this consideration, the processed peptide pre- 
cursors generated by proteolytic degradation in  the  cyto- 
plasm might also be expected to be of a similar length. An 
alternative hypothesis is that the cytosolic precursors of the 
MHC-bound  peptides  are  considerably  longer  than  the 
minimal  peptide  epitopes  (31).  Accordingly,  these  long 
precursors would be transported by the TAP complex into 
the El< and then undergo extensive trimming in the ER. 
The observations reported here suggest that processed pep- 
tide fragments  generated by the  proteasome in  the  cyto- 
plasm  are  likely  to  be  short,  i.e.,  predominantly  8-17 
amino acids in length, and therefore need not undergo ex- 
tensive modification (trimming) in the El<. 
Several reports have examined the effect ofpeptide length 
on the efficiency of ATP-dependent peptide transport by 
the TAP complex (8-10).  In general, these studies suggest 
that peptides of 9-17 aa are most efficiently transported by 
the  TAP  transporter.  One  intriguing  explanation for the 
selectivity  of MG132  inhibition  for  translation  products 
longer than 21 aa is that in the absence ofproteasome frag- 
mentation, translation products longer than 21 aa cannot be 
efficiently transported by the TAP complex. It is tempting 
to speculate that the proteasome complex involved in anti- 
gen presentation primarily generates peptide fragments of a 
defined length, e.g., 8-17 aa, which would be optimal for 
TAP-mediated transport from the cytosol to the Elk. Con- 
sistent with this view are studies on the proteolytic activity 
of purified proteasomes in vitro, which indicate that pep- 
tide fragments corresponding to the size  of minimal CTL 
epitopes can be produced from protein precursors by pro- 
teasome-dependent proteolysis (32).  However, it is equally 
likely that this multicatalytic protease complex could gen- 
erate fragments of many different lengths, i.e., from single 
aa to peptides of >20 aa in length, with varying efficien- 
cies. In this case, the constraints on peptide length imposed 
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that are of optimal length for transport, i.e., 8-17 aa. 
It is also noteworthy that among those translation prod- 
ucts  that  can be  processed in the  presence  of the  protea- 
some inhibitor,  target cells expressing the minimal transla- 
tion product were most efficiently recognized. The reasons 
for this dichotomy are not completely clear and may reflect 
differences  in  the  efficiency  of TAP-dependent  peptide 
transport  or perhaps in the  efficiency of final trimming  of 
these proteasome-independent peptides in the ER. 
In  conclusion,  our  findings  support  the  view  that  the 
proteasome complex plays a central role in antigen process- 
ing for MHC  class I-associated antigen presentation.  These 
results  further  suggest  that  the  proteasome  activity  is  re- 
quired to generate cytosolic peptides  of appropriate length 
from polypeptide  precursors  for subsequent  transport  and 
final processing. Ifpeptides of up to 16-17 aa routinely gain 
access to the ER as a result of proteasome-mediated  frag- 
mentation  and  TAP-mediated  transport,  then  final  trim- 
ming ofpeptides in the ER is likely to be an important step 
in the formation of stable peptide-MHC  complexes in the 
ER compartment. 
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